Effect of cetuximab treatment in squamous cell carcinomas
2010 (English)In: Tumor Biology, ISSN 1010-4283, E-ISSN 1423-0380, Vol. 31, no 2, 141-147 p.Article in journal (Refereed) Published
The purpose of this study was to assess the effects of the monoclonal antibody cetuximab in a panel of cultured squamous cell carcinoma cell lines. This antibody, targeting the epidermal growth factor receptor (EGFR), is emerging as a promising agent for treatment of several cancers. As this antibody comes into clinical use, the identification of predictive markers of therapeutic benefit remains a pressing issue. Cells were first characterized according to EGFR expression, cell doubling time, and BRAF and K-ras mutations. The effects of cetuximab on cell-cycle distribution, proliferation, as well as cell growth rate were then evaluated. Cetuximab decreased cell proliferation in three out of four cell lines in a time-dependent manner, and all cell lines were found to exhibit wild type K-ras and BRAF genes. A possible correlation between EGFR expression and cetuximab effect on growth inhibition rate was observed, whereas reduction of cell doubling time seemed to be more dependent on initial growth rate. In addition, other factors may further influence the long-term treatment response of cetuximab. Moreover, the time-dependent manner of cetuximab response demonstrates the importance of long-term measurements for this substance.
Place, publisher, year, edition, pages
2010. Vol. 31, no 2, 141-147 p.
Antibody, Cell proliferation, EGFR, Head and neck cancer, Squamous cell carcinoma, Cetuximab
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-130147DOI: 10.1007/s13277-010-0018-8ISI: 000278160700009PubMedID: 20358427OAI: oai:DiVA.org:uu-130147DiVA: diva2:346800